Huntsman Cancer Institute/ University of Utah Network Lead Academic Participating Site Application

作为美国国家癌症研究所（NCI）网络领先学术参与中心（NLAPS），亨斯迈癌症 研究所（HCI）将为国家临床试验网络（NCTN）提供领导和强大的应计费用 程序.正如我们之前作为NCI U10资助的NLAPS合作伙伴所取得的成功所证明的那样，HCI NLAPS将 促进与SWOG、NRG肿瘤学相关的临床试验的开发和实施， 肿瘤临床试验联盟（ALLIANCE）NCTN组，以及临床试验的实质性增加 整个NCTN的试验HCI NLAPS的执行团队在合作方面具有良好的资格和经验， 创新专项项目开展情况进行专题PI，大卫加夫尼，医学博士，博士，是一位放射肿瘤学家，具有悠久的领导历史， 参加NCTN的活动。HCI的教师通过以下方式大大提高了NCTN计划的领导力 参与指导委员会、工作队和小组活动。在过去的四年里，三名HCI教师 是国家主要研究者（PI，研究主席）;两名教员是未决试验的国家PI。 2015年，HCI晋升为综合癌症中心，获得了 “非常”。坐落在犹他州大学，在西部山区，HCI唯一的学术医疗中心 吸引了来自犹他州、爱达荷州、内华达州、蒙大拿州和怀俄明州的癌症临床试验患者， 并为这些患者群体提供近乎独家的访问。作为一个NLAPS，HCI将是一个强大的，坚定的， 作为NCTN计划的持续合作伙伴，NCTN是一个以专业知识，领导力和 主动应计。HCI将积极工作，以确保NCTN的合作努力取得成功， 根除癌症HCI有一个充满活力和不断增长的临床试验计划，并得到了 犹他州大学，大量的慈善支持，最先进的设施，一个专门的癌症医院，和 一个集中的基础设施，其临床研究企业坐落在新的，连续的空间。我们中心 也有独特的资产价值的临床研究，包括农村和美洲原住民人口，一个NCI 定量成像卓越中心和犹他州人口数据库， 基于人口的家谱数据和全州的医疗和生命记录。 HCI已经证明了其参与NCTN试验的坚定承诺。在2020年（截至10月31日）， 23%（129/543）的HCI治疗累积用于NCTN试验。超过59项NCTN治疗试验 目前开放招募，包括罕见病试验。此外，UG 1补助金第2年NCTN试验增加了 在每月10名患者的中位累积中，这超过了高绩效目标和基本奖励集 关于HCI我们要求补助金第1年的补充资金，以支持更高的应计率。

As a National Cancer Institute (NCI) Network Lead Academic Participating Site (NLAPS), Huntsman Cancer Institute (HCI) will provide leadership and robust accruals for the National Clinical Trials Network (NCTN) Program. As evidenced by our prior success as a NCI U10-funded NLAPS partner, the HCI NLAPS will contribute to the development and conduct of clinical trials in association with SWOG, NRG Oncology, and Alliance for Clinical Trials in Oncology (ALLIANCE) NCTN Groups, as well as substantial accrual to clinical trials across the entire NCTN. The HCI NLAPS executive team is well-qualified and experienced in cooperative group research. The PI, David Gaffney, MD, PhD, is a radiation oncologist with a long history of leadership and participation in NCTN activities. HCI's faculty adds significantly to the leadership of the NCTN program through participation on steering committees, task forces, and group activities. In the past four years, three HCI faculty were national principal investigators (PIs, study chairs); two faculty members are national PIs of pending trials. In 2015, HCI advanced to Comprehensive Cancer Center status, receiving an overall merit descriptor of `Exceptional'. Housed at the University of Utah, the only academic medical center in the Mountain West, HCI draws cancer clinical trial patients from across Utah, as well as from Idaho, Nevada, Montana, and Wyoming, and provides near-exclusive access to this patient population. As a NLAPS, HCI will be a strong, committed, and sustaining partner to the NCTN program as a cancer center characterized by expertise, leadership, and active accrual. HCI will work vigorously to ensure the success of the NCTN's cooperative endeavors to eradicate cancer. HCI has a vigorous and growing clinical trials program, with strong commitment from the University of Utah, substantial philanthropic support, state-of-the-art facilities, a dedicated Cancer Hospital, and a centralized infrastructure for its clinical research enterprise housed in new, contiguous space. Our Center also has unique assets of value to clinical research, including rural and Native American populations, an NCI Center for Quantitative Imaging Excellence, and the Utah Population Database, a powerful interlinkage of population based genealogical data and statewide medical and vital records. HCI has demonstrated its strong commitment to participate in NCTN trials. In the year 2020 (as of Oct 31), 23% (129/543) of HCI therapeutic accruals were to NCTN trials. More than 59 NCTN therapeutic trials are currently open to accrual, including rare disease trials. Further, UG1 Grant Year 2 NCTN trials saw an increase in the median accrual to 10 patients per month, this exceeds the High Performance target and base award set for HCI. We request supplemental funding for Grant Year 1 to support the higher accrual rates.